Business Wire

CA-ASM-GLOBAL

Share
Kai Tak Sports Park Limited and ASM Global Begin Countdown to Unveiling of World’s Largest Sports Development in History

The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire)

ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of 2025’s formal unveiling.

The project will include a 50,000-capacity main stadium with the theme “Pearl of the Orient” as its design inspiration and boasting a retractable roof and flexible pitch surface that can host a wide range of events in any weather, including major sports events, concerts and MICE events; a 10,000-capacity indoor sports arena that meets the standard of major international tournaments for a wide range of athletics, including basketball, tennis, gymnastics, family shows and other entertainment events; a 5,000-spectator, open-to-the-public sports ground for hosting school sports days, athletic meets, local football and rugby matches as well as team and athlete training sessions; and an outdoor recreation complex.

ASM Global’s President and CEO Ron Bension said, “ASM Global develops and builds spectacular venues and extraordinary entertainment districts throughout the world; but nothing compares to the scale, scope and state-of-the art innovation of Kai Tak.”

The Hong Kong site is part of ASM Global’s network of more than 400 venues around the world. The company works with major cultural and entertainment districts and venues and projects throughout the world, including Darling Harbour in Sydney, OVO Arena Wembley in London, AO Arena in Manchester and Desert Diamond in Arizona.

Officials said the expansive development will set the benchmark for multipurpose sports precincts worldwide, integrating the most advanced sports facilities with retail, wellness and community leisure spaces to create an urban oasis for the 7.4 million local community and millions of overseas visitors.

KTSPL, when awarded the contract for the design, build, construction and operation of the Kai Tak Sports Park, subsequently assembled an unparalleled project team comprising overseas and local experts in design; retail sales and marketing; construction led by Hip Hing; and ASM Global for project management, premium sales and programming.

The precinct is designed around the one-of-a-kind Kai Tak Sports Avenue. This indoor and outdoor pedestrian walk starts at Station Square and transports people completely through the immense site.

Throughout the complex will be restaurants, retail shops, jogging trails, a health and wellness center, as well as an international-standard bowling center with 40 lanes suitable for hosting international tournaments and a climbing wall on Sports Avenue.

ASM Global and KTSPL’s state-of-the-art environmentally conscious design decisions are critical to the project, intended to set and meet measurable goals to reduce impacts on the planet and champion dynamic programs for the longevity and well-being of the local community.

The focus of these sustainability efforts includes integration of photovoltaic panels on all major facilities, extensive green roofscapes and an expansive network of electric charging stations across the precinct. Smart city initiatives include an intelligent building and car management system, Wi-Fi hotspots, an indoor positioning system and mobile applications to facilitate precinct information booking of facilities and wayfinding.

Kai Tak Sports Park is expected to formally open in early 2025 and is one of the sports venues that will deliver events for the 2025 15th National Games of China that is being hosted in the Greater Bay Area.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546819/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye